| (Values in U.S. Thousands) | Sep, 2022 | Jun, 2022 | Mar, 2022 | Dec, 2021 | Sep, 2021 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -20,980 | -21,080 | -16,700 | -29,340 | -9,020 |
| Net Income Growth | +0.47% | -26.23% | +43.08% | -225.28% | -41.38% |
Cincor Pharma Inc (CINC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
CinCor Pharma Inc. is a clinical-stage biopharmaceutical company. It focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CinCor Pharma Inc. is based in BOSTON.
Fiscal Year End Date: 12/31